Article info

Download PDFPDF

Response to: ‘Comment on: ‘Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis’ by Sabbagh S et al’ by Yang et al
Free

Authors

  • Sara Sabbagh Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Iago Pinal Fernandez Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Frederick W Miller Environmental Autoimmunity Group, National Institute of Environmental Health Sciences/National Institutes of Health/Department of Health and Human Services, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Lisa G Rider Environmental Autoimmunity Group, National Institute of Environmental Health Sciences/National Institutes of Health/Department of Health and Human Services, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Andrew Lee Mammen Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Andrew Lee Mammen, NIAMS/NIH, Bethesda, MD 20892, USA; andrew.mammen{at}nih.gov
View Full Text

Citation

Sabbagh S, Pinal Fernandez I, Miller FW, et al
Response to: ‘Comment on: ‘Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis’ by Sabbagh S et al’ by Yang et al

Publication history

  • Received May 30, 2019
  • Revised June 3, 2019
  • Accepted June 4, 2019
  • First published June 17, 2019.
Online issue publication 
July 13, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.